CYP19A1 and neoplasm: Patients receiving neo-adjuvant treatment with the AIs experience a profound suppression of oestrogen levels, and the suppression of oestrogen in tumour is comparable with the fall in plasma oestrogen levels and in vivo total body aromatase inhibition (Geisler et al, 2001, 2002, 2008).